The company’s approved product, Zulresso (brexanolone injection), is the first FDA-approved treatment for postpartum depression (PPD). Sage is also advancing zuranolone, an oral therapy under development for major depressive disorder (MDD) and PPD, designed for short-course use with the potential to rapidly relieve symptoms. Other pipeline candidates, such as SAGE-324 for essential tremor and SAGE-718 for cognitive disorders, further highlight Sage's focus on addressing CNS conditions.

In January 2024, Biogen (Nasdaq: BIIB) submitted an unsolicited, nonbinding proposal to acquire all outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.